Shailesh Kolekar

Shailesh Kolekar

Auto-generated profile, based on publicly available information

Shailesh Kolekar

Department of Clinical Medicine (IKM), University of Copenhagen, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 December 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CHChi Yan Hui
Chi Yan Hui
KCKathleena Condon
Kathleena Condon
SKShailesh Kolekar
Shailesh Kolekar
NRNicola Roberts
Nicola Roberts
KSKatherina Bernadette Sreter
Katherina Bernadette Sreter
ACAmy Hai Yan Chan
Amy Hai Yan Chan
The value of ‘data-enabled’, digital healthcare is evolving rapidly, as demonstrated in the COVID-19 pandemic, and its successful implementation remains complex and challenging. Harmonisation (within/between healthcare systems) of infrastructure and implementation strategies has the potential to promote safe, equitable and accessible digital healthcare, but guidance for implementation is lacking. Using respiratory technologies as an example, our scoping review process will capture and review the published research between 12th December 2013 to 12th December 2023. Following standard methodology (Arksey and O’Malley), we will search for studies published in ten databases: MEDLINE, EMBASE, CINAHL, PsycINFO, Cochrane Library, Web of Science, Scopus, IEEE Xplore, CABI Global Health, and WHO Medicus. Our search strategy will use the terms: digital health, respiratory conditions, and implementation. Using Covidence, screening of abstracts and full texts will be undertaken by two independent reviewers, with conflicts resolved by a third reviewer. Data will be extracted into a pilot-tested data extraction table for charting, summarising and reporting the results. We will conduct stakeholder meetings throughout to discuss the themes emerging from implementation studies and support interpretation of findings in the light of their experience within their own networks and organisations. The findings will inform the future work within the ERS CONNECT clinical research collaboration and contribute to policy statements to promote a harmonised framework for digital transformation of respiratory healthcare.

1 March 2023 in International Journal of Chronic Obstructive Pulmonary Disease
Verified
Journal Article
Open access
PDF file
CHChristian Kjer Heerfordt
Christian Kjer Heerfordt
JEJosefin Eklöf
Josefin Eklöf
PSPradeesh Sivapalan
Pradeesh Sivapalan
TITruls Sylvan Ingebrigtsen
Truls Sylvan Ingebrigtsen
TBTor Biering-Sørensen
Tor Biering-Sørensen
Jens Ulrik Stæhr JensenJens Ulrik Stæhr Jensen
Jens Ulrik Stæhr Jensen
Background: Inhaled corticosteroids (ICS) are associated with an increased risk of clinical pneumonia among patients with chronic obstructive pulmonary disease (COPD). It is unknown whether the risk of microbiologically verified pneumonia such as pneumococcal pneumonia is increased in ICS users. Methods: The study population consists of all COPD patients followed in outpatient clinics in eastern Denmark during 2010– 2017. ICS use was categorized into four categories based on accumulated use. A Cox proportional hazard regression model was used adjusting for age, body mass index, sex, airflow limitation, use of oral corticosteroids, smoking, and year of cohort entry. A propensity score matched analysis was performed for sensitivity analyses. Findings: A total of 21,438 patients were included. Five hundred and eighty-two (2.6%) patients acquired a positive lower airway tract sample with S. pneumoniae during follow-up. In the multivariable analysis ICS-use was associated with a dose-dependent risk of S. pneumoniae as follows: low ICS dose: HR 1.11, 95% CI 0.84 to 1.45, p = 0.5; moderate ICS dose: HR 1.47, 95% CI 1.13 to 1.90, p = 0.004; high ICS dose: HR 1.77, 95% CI 1.38 to 2.29, p < 0.0001, compared to no ICS use. Sensitivity analyses confirmed these results. Interpretation: Use of ICS in patients with severe COPD was associated with an increased and dose-dependent risk of acquiring S. pneumoniae, but only for moderate and high dose. Caution should be taken when administering high dose of ICS to patients with COPD. Low dose of ICS seemed not to carry this risk.

29 October 2018 in European Journal of Clinical Microbiology & Infectious Diseases
Verified
Journal Article
Closed access
PDF file
KJKatrine M Johannesen
Katrine M Johannesen
SKShailesh B. Kolekar
Shailesh B. Kolekar
NGNikolaos Greve
Nikolaos Greve
XNXiaohui Chen Nielsen
Xiaohui Chen Nielsen
TBToke Seierøe Barfod
Toke Seierøe Barfod
UBUffe Bødtger
Uffe Bødtger

15 June 2023 in ERJ Open Research
Verified
Journal Article
Open access
PDF file
AVAngelos Vontetsianos
Angelos Vontetsianos
DGDamla Karadeniz Güven
Damla Karadeniz Güven
SBSophie Betka
Sophie Betka
SSSara Souto-Miranda
Sara Souto-Miranda
MMMathieu Marillier
Mathieu Marillier
TGThomas Gille
Thomas Gille
It is a challenge to keep abreast of all the clinical and scientific advances in the field of respiratory medicine. This article contains an overview of the laboratory-based science, clinical trials and qualitative research that were presented during the 2022 European Respiratory Society International Congress within the sessions from the five groups of Assembly 1 (Respiratory Clinical Care and Physiology). Selected presentations are summarised from a wide range of topics: clinical problems, rehabilitation and chronic care, general practice and primary care, mobile/electronic health (m-health/e-health), clinical respiratory physiology, exercise and functional imaging.

1 April 2022 in ERJ Open Research
Verified
Journal Article
Open access
PDF file
TGThomas Gille
Thomas Gille
Pradeesh SivapalanPradeesh Sivapalan
Pradeesh Sivapalan
GKGeorgios Kaltsakas
Georgios Kaltsakas
SKShailesh B. Kolekar
Shailesh B. Kolekar
MAMatthew Armstrong
Matthew Armstrong
LVLowie Vanfleteren
Lowie Vanfleteren
It is a challenge to keep abreast of all the clinical and scientific advances in the field of respiratory medicine. This article contains an overview of laboratory-based science, randomised controlled trials and qualitative research that were presented during the 2021 European Respiratory Society International Congress within the sessions from the five groups of the Assembly 1 – Respiratory clinical care and physiology. Selected presentations are summarised from a wide range of topics: clinical problems, rehabilitation and chronic care, general practice and primary care, electronic/mobile health (e-health/m-health), clinical respiratory physiology, exercise and functional imaging.

10 November 2021 in Respiratory Medicine Case Reports
Verified
Journal Article
Open access
SKShailesh Kolekar
Shailesh Kolekar
KGKristrun Gudmundsdottir
Kristrun Gudmundsdottir
KOKaren Ege Olsen
Karen Ege Olsen
Pradeesh SivapalanPradeesh Sivapalan
Pradeesh Sivapalan
PCPaul Frost Clementsen
Paul Frost Clementsen
UBUffe Bødtger
Uffe Bødtger
Pulmonary blastoma is an aggressive lung cancer with incidence ranging from 0.25–0.5 of all the reported lung cancers. Although, pulmonary blastoma is seen commonly in childhood its very rare in adults. Surgical treatment is often the treatment of choice, but benefits of neoadjuvant chemotherapy are unclear. People with DICER1 syndrome commonly develop Pulmonary blastoma and do have concomitant or previous history of benign or malignant tumours in extra pulmonary site like kidney, thyroid, ovary cervix testicle and eye. As per our knowledge, this is the first case of adult pulmonary blastoma previously diagnosed with urothelial cancer and a strong familial predilection of malignancy, with negative genetic test for DICER1 mutations.